# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

> **NCT00605475** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 231 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00605475
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2012-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605475, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00605475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*